JP2016525124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525124A5 JP2016525124A5 JP2016527147A JP2016527147A JP2016525124A5 JP 2016525124 A5 JP2016525124 A5 JP 2016525124A5 JP 2016527147 A JP2016527147 A JP 2016527147A JP 2016527147 A JP2016527147 A JP 2016527147A JP 2016525124 A5 JP2016525124 A5 JP 2016525124A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- inhibitor
- agent
- dnmt
- immune cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 41
- 210000002865 immune cell Anatomy 0.000 claims 23
- 239000003112 inhibitor Substances 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 23
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 230000001225 therapeutic effect Effects 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 21
- 210000001744 T-lymphocyte Anatomy 0.000 claims 14
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 13
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 12
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 10
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 10
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 8
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 6
- 229960002756 azacitidine Drugs 0.000 claims 6
- 239000003226 mitogen Substances 0.000 claims 6
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 claims 6
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 6
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 4
- 102000003964 Histone deacetylase Human genes 0.000 claims 4
- 108090000353 Histone deacetylase Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 229960003603 decitabine Drugs 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 4
- 108010091666 romidepsin Proteins 0.000 claims 4
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims 4
- 229960000604 valproic acid Drugs 0.000 claims 4
- 229940061261 zolinza Drugs 0.000 claims 4
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims 2
- 108010069514 Cyclic Peptides Proteins 0.000 claims 2
- 102000001189 Cyclic Peptides Human genes 0.000 claims 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 2
- 102000016397 Methyltransferase Human genes 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- PAWIYAYFNXQGAP-UHFFFAOYSA-N N-hydroxy-2-[4-[[(1-methyl-3-indolyl)methylamino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide Chemical compound C12=CC=CC=C2N(C)C=C1CNCC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 PAWIYAYFNXQGAP-UHFFFAOYSA-N 0.000 claims 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims 2
- GUWXKKAWLCENJA-WGWHJZDNSA-N [(2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2r,3s,5r)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)C1 GUWXKKAWLCENJA-WGWHJZDNSA-N 0.000 claims 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 2
- 229960003094 belinostat Drugs 0.000 claims 2
- 229940054066 benzamide antipsychotics Drugs 0.000 claims 2
- 150000003936 benzamides Chemical class 0.000 claims 2
- 229940057372 buphenyl Drugs 0.000 claims 2
- 235000004883 caffeic acid Nutrition 0.000 claims 2
- 229940074360 caffeic acid Drugs 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 235000001368 chlorogenic acid Nutrition 0.000 claims 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims 2
- 229940074393 chlorogenic acid Drugs 0.000 claims 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 239000005549 deoxyribonucleoside Chemical class 0.000 claims 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 2
- 229940075925 depakote Drugs 0.000 claims 2
- JROGBPMEKVAPEH-GXGBFOEMSA-N emetine dihydrochloride Chemical compound Cl.Cl.N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC JROGBPMEKVAPEH-GXGBFOEMSA-N 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 2
- 229950005837 entinostat Drugs 0.000 claims 2
- 229940030275 epigallocatechin gallate Drugs 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000004068 intracellular signaling Effects 0.000 claims 2
- 229940011083 istodax Drugs 0.000 claims 2
- 230000011987 methylation Effects 0.000 claims 2
- 238000007069 methylation reaction Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 229960005184 panobinostat Drugs 0.000 claims 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- ABTXGJFUQRCPNH-UHFFFAOYSA-N procainamide hydrochloride Chemical compound [H+].[Cl-].CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 ABTXGJFUQRCPNH-UHFFFAOYSA-N 0.000 claims 2
- 229960003253 procainamide hydrochloride Drugs 0.000 claims 2
- 229950010654 quisinostat Drugs 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 229960003452 romidepsin Drugs 0.000 claims 2
- 235000021391 short chain fatty acids Nutrition 0.000 claims 2
- 150000004666 short chain fatty acids Chemical class 0.000 claims 2
- 229960002232 sodium phenylbutyrate Drugs 0.000 claims 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 2
- 229940065658 vidaza Drugs 0.000 claims 2
- 229960000237 vorinostat Drugs 0.000 claims 2
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 125000003835 nucleoside group Chemical class 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361847957P | 2013-07-18 | 2013-07-18 | |
| US61/847,957 | 2013-07-18 | ||
| PCT/US2014/047311 WO2015010096A1 (en) | 2013-07-18 | 2014-07-18 | Method of enhancing potency of immune cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019125649A Division JP2019196372A (ja) | 2013-07-18 | 2019-07-05 | 免疫細胞の能力を増強する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525124A JP2016525124A (ja) | 2016-08-22 |
| JP2016525124A5 true JP2016525124A5 (enExample) | 2017-08-10 |
| JP6585041B2 JP6585041B2 (ja) | 2019-10-02 |
Family
ID=51293177
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527147A Active JP6585041B2 (ja) | 2013-07-18 | 2014-07-18 | 免疫細胞の能力を増強する方法 |
| JP2019125649A Pending JP2019196372A (ja) | 2013-07-18 | 2019-07-05 | 免疫細胞の能力を増強する方法 |
| JP2021113697A Pending JP2021176863A (ja) | 2013-07-18 | 2021-07-08 | 免疫細胞の能力を増強する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019125649A Pending JP2019196372A (ja) | 2013-07-18 | 2019-07-05 | 免疫細胞の能力を増強する方法 |
| JP2021113697A Pending JP2021176863A (ja) | 2013-07-18 | 2021-07-08 | 免疫細胞の能力を増強する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US10279009B2 (enExample) |
| EP (1) | EP3021853A1 (enExample) |
| JP (3) | JP6585041B2 (enExample) |
| WO (1) | WO2015010096A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015179801A1 (en) | 2014-05-23 | 2015-11-26 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| US10647778B2 (en) | 2015-02-09 | 2020-05-12 | University Of Florida Research Foundation, Incorporated | Bi-specific chimeric antigen receptor and uses thereof |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| IL303543A (en) | 2015-02-18 | 2023-08-01 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2016134284A1 (en) * | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| CN113106053A (zh) | 2015-04-21 | 2021-07-13 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
| ES2877090T3 (es) | 2015-08-05 | 2021-11-16 | Cellabmed Inc | Receptor de antígenos quiméricos y células T en las que se expresa el receptor de antígenos quiméricos |
| EP3416661A4 (en) | 2016-02-18 | 2020-03-04 | Enlivex Therapeutics Ltd. | COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER |
| WO2017190096A1 (en) | 2016-04-29 | 2017-11-02 | University Of Florida Research Foundation Incorporated | Chimeric antigen receptors and uses thereof |
| JP7373991B2 (ja) * | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| SG10202111394XA (en) * | 2017-04-13 | 2021-12-30 | Senti Biosciences Inc | Combinatorial cancer immunotherapy |
| TWI676483B (zh) * | 2017-08-06 | 2019-11-11 | 強普生技股份有限公司 | 醫藥套組及其用途 |
| JP7654240B2 (ja) | 2017-09-19 | 2025-04-01 | マサチューセッツ インスティテュート オブ テクノロジー | キメラ抗原受容体ｔ細胞治療のための組成物およびその使用 |
| JP2021511293A (ja) * | 2018-01-12 | 2021-05-06 | ビラクタ セラピューティクス，インク． | 細胞免疫療法で使用されるエピジェネティック修飾因子 |
| CN112812153B (zh) * | 2018-02-15 | 2022-06-14 | 国立大学法人旭川医科大学 | 癌症抗原肽 |
| SG11202011028SA (en) * | 2018-05-11 | 2020-12-30 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| KR102069704B1 (ko) * | 2018-05-16 | 2020-01-23 | 고려대학교 산학협력단 | Hdac 억제제를 이용한 사람 유래 자연살해세포의 확장 배양법 |
| CN109306341B (zh) * | 2018-09-12 | 2022-01-28 | 华东师范大学 | Hdac11基因干扰的嵌合抗原受体t细胞及其应用 |
| AU2019346335B2 (en) | 2018-09-28 | 2024-07-25 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| GB201816644D0 (en) * | 2018-10-12 | 2018-11-28 | Autolus Ltd | Vectors |
| EP3884055B1 (en) | 2018-11-07 | 2023-08-09 | Consejo Superior de Investigaciones Científicas (CSIC) | Double and inducible suicide gene construct and its use in gene therapy |
| EP3656851A1 (en) * | 2018-11-23 | 2020-05-27 | Technische Universität Dresden | Artificial hla-positive feeder cell lines for nk cells and uses thereof |
| CN113543792A (zh) * | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
| EP3990491A1 (en) | 2019-06-26 | 2022-05-04 | Massachusetts Institute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| US12485174B2 (en) | 2019-06-27 | 2025-12-02 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | HDAC6-activated macrophages, compositions, and uses thereof |
| WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
| CA3173527A1 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
| JP2023517889A (ja) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法 |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| US12433954B2 (en) | 2020-05-01 | 2025-10-07 | Massachusetts Institute Of Technology | Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs |
| CN113502265B (zh) * | 2021-05-25 | 2024-05-28 | 昭泰英基生物医药（香港）有限公司 | 将t细胞重编程为类nk细胞的诱导剂及其应用 |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| WO2024254774A1 (zh) * | 2023-06-14 | 2024-12-19 | 香港北恒生物科技有限公司 | 免疫细胞联合疗法 |
| CN118059217B (zh) * | 2023-12-20 | 2025-02-28 | 西安电子科技大学 | 一种表观遗传药物联合过继单核/巨噬细胞免疫治疗在制备肿瘤疾病生物药品中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8530445B2 (en) * | 2008-06-09 | 2013-09-10 | Cyclacel Limited | Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine |
| NZ723731A (en) | 2011-04-08 | 2020-05-29 | Baylor College Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| WO2013050596A1 (en) | 2011-10-06 | 2013-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of maintaining foxp3 expression in expanded t regulatory cell |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
-
2014
- 2014-07-18 JP JP2016527147A patent/JP6585041B2/ja active Active
- 2014-07-18 US US14/335,766 patent/US10279009B2/en active Active
- 2014-07-18 EP EP14748058.6A patent/EP3021853A1/en not_active Withdrawn
- 2014-07-18 WO PCT/US2014/047311 patent/WO2015010096A1/en not_active Ceased
-
2019
- 2019-03-21 US US16/360,785 patent/US11547740B2/en active Active
- 2019-07-05 JP JP2019125649A patent/JP2019196372A/ja active Pending
-
2021
- 2021-07-08 JP JP2021113697A patent/JP2021176863A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525124A5 (enExample) | ||
| JP2016536341A5 (enExample) | ||
| Sehrawat et al. | Interplay of regulatory T cell and Th17 cells during infectious diseases in humans and animals | |
| D’Addio et al. | The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance | |
| Juno et al. | Invariant NKT cells: regulation and function during viral infection | |
| Biron et al. | NK cells and NKT cells in innate defense against viral infections | |
| Lazarevic et al. | T-bet: a bridge between innate and adaptive immunity | |
| JP2021176863A5 (enExample) | ||
| Freudenberg et al. | Critical role of TGF-β and IL-2 receptor signaling in Foxp3 induction by an inhibitor of DNA methylation | |
| EP4357355A3 (en) | Virus purification | |
| Morre et al. | Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival | |
| RU2017139121A (ru) | Композиции для модулирования экспрессии c9orf72 | |
| BR112016013187A2 (pt) | receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos | |
| CL2021002460A1 (es) | Péptidos, anticuerpos, tcr, célula hospedadora, linfocito t activado, composición farmacéutica, y sus usos en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| PE20240645A1 (es) | Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores | |
| MX355074B (es) | Inmunoterapia novedosa contra varios tumores incluidos el cancer gastrico y gastrointestinal. | |
| EA201790953A1 (ru) | Изменение экспрессии гена в cart-клетках и их применения | |
| EP3525801A1 (en) | Medical uses of exosomes | |
| JP2016519933A5 (enExample) | ||
| MX374267B (es) | Conjugados novedosos de analogos cc-1065 y ligaduras bifuncionales. | |
| AR078423A1 (es) | Vacunas dirigidas a las celulas de langerhans | |
| HRP20180377T1 (hr) | Proizvodi i postupci za modulaciju liječenja tetiva | |
| EP4470623A3 (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and ppropagation of same | |
| MX2017006639A (es) | Metodos y composiciones para preservar la masa corporal magra y promover la perdida de grasa durante la perdida de peso. |